Stroke Prevention in Atrial Fibrillation – Outcomes and Future Directions
Key result
Once-daily edoxaban is non-inferior to warfarin for preventing stroke or systemic embolism in AF.
Why the study?
Do NOACs prevent stroke and reduce bleeding compared to VKAs in patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Comparison
Non-VKA oral anticoagulants including… vs Vitamin K antagonists / dose-adjusted warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports edoxaban as alternative to warfarin in AF; confirms NOAC class effect while leaving real-world implementation open.
Structured PICO
Do NOACs prevent stroke and reduce bleeding compared to VKAs in patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation
I
Intervention
Non-VKA oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
C
Comparator
Vitamin K antagonists (VKAs) / dose-adjusted warfarin
O
Outcome
Prevention of stroke or systemic embolismhard clinical
NOACs offer a non-inferior, safer alternative to VKAs for stroke prevention in atrial fibrillation, though global uptake remains suboptimal.
Cite This Study
Mountfort et al. (2014) conducted a review in Atrial fibrillation. Edoxaban vs. Dose-adjusted warfarin (INR 2.0-3.0) was evaluated on Stroke or systemic embolism. Once-daily edoxaban was non-inferior to well-managed warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation.